This month, the CONQUEST team traveled to Madrid, Spain and Amsterdam in the Netherlands to continue building global awareness of the CONQUEST clinical trial.
CONQUEST is a groundbreaking platform clinical trial created by the Scleroderma Research Foundation, in collaboration with biopharmaceutical partners, to accelerate the development of potential new treatments for scleroderma.
These international visits are part of CONQUEST’s effort to establish a global network of treatment centers, engage with the broader rheumatology community, and advance research for people living with scleroderma worldwide.
CONQUEST is currently enrolling patients for its iteration focused on SSc-ILD. If you or someone you know is living with this condition, consider enrolling. Take the pre-screener survey and learn more about how to participate on the CONQUEST website.
